Published in Breast Cancer Res on June 28, 2001
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta (2006) 7.33
Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem (2006) 1.83
Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. Cancer Res (2010) 1.81
mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacol Ther (2006) 1.56
Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res (2011) 1.39
New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res (2004) 1.20
Down-regulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells. Mol Pharmacol (2006) 1.14
Activation of Robo1 signaling of breast cancer cells by Slit2 from stromal fibroblast restrains tumorigenesis via blocking PI3K/Akt/β-catenin pathway. Cancer Res (2012) 1.11
Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells. Breast Cancer Res (2005) 1.05
Calcium regulation of keratinocyte differentiation. Expert Rev Endocrinol Metab (2012) 1.03
PI3K/AKT inhibition induces caspase-dependent apoptosis in HTLV-1-transformed cells. Virology (2007) 0.96
PI3K activation is associated with intracellular sodium/iodide symporter protein expression in breast cancer. BMC Cancer (2007) 0.96
Synergistic effect of ERK inhibition on tetrandrine-induced apoptosis in A549 human lung carcinoma cells. J Vet Sci (2009) 0.95
Metabolic consequences of treatment with AKT inhibitor perifosine in breast cancer cells. NMR Biomed (2011) 0.90
Coupling in vitro and in vivo paradigm reveals a dose dependent inhibition of angiogenesis followed by initiation of autophagy by C6-ceramide. Int J Biol Sci (2011) 0.81
Exploring the role of two interacting phosphoinositide 3-kinases of Haemonchus contortus. Parasit Vectors (2014) 0.77
Induction of methionine adenosyltransferase 2A in tamoxifen-resistant breast cancer cells. Oncotarget (2016) 0.76
Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. Cancer Res (2017) 0.76
Detecting phenotype-specific interactions between biological processes from microarray data and annotations. IEEE/ACM Trans Comput Biol Bioinform (2012) 0.76
Human activated macrophages and hypoxia: a comprehensive review of the literature. Iran J Basic Med Sci (2014) 0.75
PI3K signaling in Leishmania infections. Cell Immunol (2016) 0.75
Neuroprotective Effects of Salidroside in the MPTP Mouse Model of Parkinson's Disease: Involvement of the PI3K/Akt/GSK3β Pathway. Parkinsons Dis (2016) 0.75
Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science (1999) 6.93
The many substrates and functions of ATM. Nat Rev Mol Cell Biol (2000) 5.46
Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature (2000) 4.92
Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res (1999) 4.79
The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res (1999) 4.66
Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem (2001) 3.86
Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet (1997) 3.66
Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr Opin Cell Biol (1999) 3.47
Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem (1998) 3.25
A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci U S A (2001) 3.01
Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem (1999) 2.89
Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol (1999) 2.79
PIK3CA as an oncogene in cervical cancer. Oncogene (2000) 2.75
Phosphoinositide signaling and the regulation of membrane trafficking in yeast. Trends Biochem Sci (2000) 2.72
Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet (1996) 2.59
Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation. Curr Opin Genet Dev (1999) 2.48
Requirement for both Shc and phosphatidylinositol 3' kinase signaling pathways in polyomavirus middle T-mediated mammary tumorigenesis. Mol Cell Biol (1998) 2.48
Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response. Nature (2000) 2.44
Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product. J Biol Chem (1994) 2.44
Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res (2000) 2.14
The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochim Biophys Acta (2000) 2.05
Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol (2001) 2.02
Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 3'-kinase and phospholipase C-dependent mechanism. Cancer Res (1999) 1.98
Distinct roles for the p110alpha and hVPS34 phosphatidylinositol 3'-kinases in vesicular trafficking, regulation of the actin cytoskeleton, and mitogenesis. J Cell Biol (1998) 1.97
BRK tyrosine kinase expression in a high proportion of human breast carcinomas. Oncogene (1997) 1.77
Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmannin. Biochem J (1997) 1.60
Ataxia telangiectasia mutated (ATM) kinase and ATM and Rad3 related kinase mediate phosphorylation of Brca1 at distinct and overlapping sites. In vivo assessment using phospho-specific antibodies. J Biol Chem (2001) 1.60
A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology (2000) 1.59
Brk, a breast tumor-derived non-receptor protein-tyrosine kinase, sensitizes mammary epithelial cells to epidermal growth factor. J Biol Chem (1996) 1.56
PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways. Hum Mol Genet (2001) 1.56
Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors. Mol Cell Biol (2000) 1.55
Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations. Mol Genet Metab (1999) 1.50
Expression of the BRK tyrosine kinase in mammary epithelial cells enhances the coupling of EGF signalling to PI 3-kinase and Akt, via erbB3 phosphorylation. Oncogene (2000) 1.48
Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer. Mol Endocrinol (2000) 1.46
Structure, regulation and function of phosphoinositide 3-kinases. Biochim Biophys Acta (1994) 1.45
Phosphatidylinositol 3-kinases in tumor progression. Eur J Biochem (2001) 1.38
Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Oncogene (1998) 1.38
Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice. BMC Mol Biol (2001) 1.36
Ataxia telangiectasia-related protein is involved in the phosphorylation of BRCA1 following deoxyribonucleic acid damage. Cancer Res (2000) 1.26
ERBB-2 overexpression confers PI 3' kinase-dependent invasion capacity on human mammary epithelial cells. Br J Cancer (2000) 1.24
Role of AKT1 in 17beta-estradiol- and insulin-like growth factor I (IGF-I)-dependent proliferation and prevention of apoptosis in MCF-7 breast carcinoma cells. Biochem Pharmacol (1999) 1.23
PI3-kinase inhibition: a target for drug development? Mol Med Today (2000) 1.23
In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res (1995) 1.20
The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage. Cancer Res (1996) 1.16
Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-Kinase/AKT in breast cancer cells. J Biol Chem (1999) 1.15
Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. Cell Growth Differ (2000) 1.13
Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification. Cell Growth Differ (1996) 0.99
Stabilization of cyclin D1 mRNA via the phosphatidylinositol 3-kinase pathway in MCF-7 human breast cancer cells. J Endocrinol (2000) 0.94
Identification of four novel human phosphoinositide 3-kinases defines a multi-isoform subfamily. Biochem Biophys Res Commun (1997) 0.89
Wortmannin, a phosphoinositide 3-kinase inhibitor, selectively enhances cytotoxicity of receptor-directed-toxin chimeras in vitro and in vivo. Anticancer Res (1999) 0.87
Phospatidylinositol 3-kinase expression in human breast cancer. Clin Chim Acta (1999) 0.87
cDNA cloning of a third human C2-domain-containing class II phosphoinositide 3-kinase, PI3K-C2gamma, and chromosomal assignment of this gene (PIK3C2G) to 12p12. Genomics (1998) 0.86
Identification and cDNA cloning of a novel mammalian C2 domain-containing phosphoinositide 3-kinase, HsC2-PI3K. Biochem Biophys Res Commun (1997) 0.85
Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase. Cancer Chemother Pharmacol (1999) 0.83
Estrogen receptor is associated with protein and phospholipid kinase activities. Biochem Biophys Res Commun (1986) 0.82
[Rapamycin and CCI-779]. Bull Cancer (1999) 0.81